Virogin Company
They are dedicated to developing the next generation of oncolytic virus (OV) therapeutics using their novel Synerlytic™ technical platform for improved cancer treatment. By exploring innovative approaches to immunotherapy, Virogin is committed to becoming a world leader in the field of immuno-oncology.
Investment Stage:
Venture
Founded Date:
2015
Investor Type:
Undisclosed
Employee Number:
Undisclosed
Number Of Exists:
1
Industry:
Drug Discovery
Technology:
Drug Design
Headquarters:
Shenzhen, Guangdong, China
Funding Status:
N/A